Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Up 724.0% in February

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 85,700 shares, an increase of 724.0% from the February 13th total of 10,400 shares. Based on an average daily volume of 2,040,000 shares, the short-interest ratio is presently 0.0 days. Currently, 5.5% of the company’s stock are sold short.

Salarius Pharmaceuticals Stock Down 1.1 %

Shares of Salarius Pharmaceuticals stock traded down $0.01 during midday trading on Wednesday, hitting $0.94. The company had a trading volume of 19,085 shares, compared to its average volume of 1,225,098. The stock has a market cap of $1.48 million, a price-to-earnings ratio of -0.11 and a beta of 0.59. Salarius Pharmaceuticals has a 12-month low of $0.91 and a 12-month high of $7.20. The company has a fifty day simple moving average of $1.84 and a 200 day simple moving average of $1.65.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.